RTCA ePacer Software
Drive Functional Maturation of hiPSC Cardiomyocytes with Precise Electrical Pacing
- The xCELLigence RTCA ePacer Software enables an easy and effective way to produce functionally mature hiPSC cardiomyocyte using precise and electrical pacing conditions over different time durations. The simple pacing protocol improves the functionality of hiPSC Cardiomyocytes and their response to inotropic compounds
- Flexible integration into your existing assay workflow.
- Convenient view area on the E-Plate Cardio View 96 allows for compatibility with other optical assays.
- Extensive application functionally for cardiomyocyte workflows
- Obtain more physiological relevant models with functionally mature hiPSC cardiomyocytes
- Precise control of beating rate and pacing conditions over different time durations produces functional and mature cardiomyocytes
Overview
How it works
Tunable pacing function
Stimulus settings, such as pulse type, pulse intensity, pulse length, and stimulation duration can be easily selected and defined by the user.
Independent pacing settings for individual columns and plates
Stimulus settings can be applied based on individual columns or across different plates.
Quick and easy way to evaluate cell maturation status using force-frequency relationship calculation
The built-in algorithm automatically generates force-frequency relationship curves before and after long-term pacing process.
Tools
Agilent Cell Analysis Publication Database
Search scientific publications by research area, cell type and more.
Agilent Cell Analysis Webinars
Featured webinars help you stay informed about timely cell analysis research topics.
Training & events
Agilent Cell Analysis Webinar Series
View informative Agilent Cell Analysis Technology webinars on a variety of research subjects.
News
Agilent xCELLigence RTCA Instrumentation Supports Potency Assay Development in Recent FDA Approval
Agilent xCELLigence Real-Time Cell Analysis (RTCA) technology supports the testing of accuracy and reliability in AUCATZYL, a recently approved CAR T therapy by Autolus Therapeutics. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis capabilities, Agilent supported Autolus's efforts in establishing robust analytical methods.
15 Jul 2025
